Abstract：
:Oseltamivir phosphate is an FDA-approved treatment for influenza that has been available for prescription use in the USA since 1999. The present report describes findings from a post-marketing safety study of skin reactions associated with oseltamivir use. All patients in the claims-derived Ingenix Research Database with a physician diagnosis of influenza and/or a dispensing of oseltamivir between 1 December 1999 and 31 March 2002 were identified. Cohort eligibility criteria included minimum baseline enrolment duration of 3 months, age of at least 1 year and no influenza vaccination on the date of influenza diagnosis or oseltamivir dispensing. Patients were classified into two primary cohorts, influenza diagnosis and oseltamivir dispensing on the same day, and influenza diagnosis but no oseltamivir at any time, and a cohort included for secondary analyses comprising patients who received an oseltamivir dispensing without an influenza diagnosis on the same day. Outcomes included general skin reactions and several specific skin reactions. Events occurring during the 30 days following the date of influenza diagnosis or oseltamivir dispensing were examined using Cox proportional hazards models. Model covariates included age, use of another influenza drug, month and year of index date, and use of antitussives. Adjusted rate ratios for the general class of skin reactions among the primary cohort of oseltamivir users versus non-users were 1.05 (95% CI: 0.88-1.24) for incident cases and 0.98 (95% CI: 0.77-1.24) among patients with a history of a skin reaction. Similar results were seen for the other skin reaction categories, and secondary analyses investigating the oseltamivir users without influenza revealed no elevation in risk. It is concluded that oseltamivir use does not appear to be associated with an increased risk of skin reactions.
journal_name
Antivir Therjournal_title
Antiviral therapyauthors
Nordstrom BL,Oh K,Sacks ST,L'Italien GJsubject
Has Abstractpub_date
2004-04-01 00:00:00pages
187-95issue
2eissn
1359-6535issn
2040-2058journal_volume
9pub_type
杂志文章abstract：BACKGROUND:US guidelines recommend genotyping for persons newly diagnosed with HIV infection to identify transmitted drug resistance mutations associated with decreased susceptibility to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors. To date, testin...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2780
更新日期：2015-01-01 00:00:00
abstract：:Drug-drug interactions in HIV therapy have been known to the clinic from earliest days of HIV treatment. Hundreds of well-designed pharmacokinetic studies have been performed in either HIV-infected patients or, mostly, in healthy volunteers. Case reports generally are graded lower in terms of evidence-based medicine b...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2688
更新日期：2013-01-01 00:00:00
abstract：BACKGROUND:Two distinct inhibitors of the HCV protease have been approved for the treatment of patients infected with HCV genotype-1. These drugs are highly efficient in suppressing HCV replication; however, their use is limited by the emergence of viral mutants resistant to them after a very short time of treatment. B...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2326
更新日期：2013-01-01 00:00:00
abstract：BACKGROUND:Strong hepatitis C virus (HCV)-specific T-cell responses are associated with spontaneous clearance of acute hepatitis C. However, recent studies described a decline in HCV-specific CD8+ T-cells during interferon treatment, suggesting that the success of acute HCV therapy might be independent of adaptive immu...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported. The aim of this study was to investigate the association of IR ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2743
更新日期：2014-01-01 00:00:00
abstract：:Although zidovudine (ZDV) is effective in HIV-1-infected patients, the duration of its efficacy may be short when treatment is started in advanced HIV disease. This pilot prospective case-control study was designed to evaluate the combination of ZDV plus didanosine [ddI] compared with ZDV monotherapy as an initial the...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章
doi：
更新日期：1996-04-01 00:00:00
abstract：BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2006-01-01 00:00:00
abstract：:There are many potential reasons for increased liver-related mortality in HIV-hepatitis B virus (HBV) coinfection compared with either infection alone. HIV infects multiple cells in the liver and might potentially alter the life cycle of HBV, although evidence to date is limited. Unique mutations in HBV have been defi...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：
更新日期：2009-01-01 00:00:00
abstract：OBJECTIVE:To assess the effect of interleukin (IL)-2 combined with highly active antiretroviral therapy (HAART) on HIV-1 pro-viral DNA quantification in HIV-1-infected patients with CD4<200/mm3. PATIENTS AND METHODS:Seventy patients with CD4<200 cells/mm3 and CV<1000 copies/ml were enrolled in a 6-month randomized con...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：2003-06-01 00:00:00
abstract：BACKGROUND:Although antiretroviral therapy during pregnancy is associated with significant reductions in the risk of vertical transmission of HIV, attainment of this outcome in highly treatment-experienced pregnant women might be complicated by the lack of active drugs available to assemble a potent regimen. The recent...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1558
更新日期：2010-01-01 00:00:00
abstract：BACKGROUND:In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of variousnucleoside/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal obs...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,多中心研究
doi：10.3851/IMP3205
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND:Antiviral and immune-modulating properties of low-molecular-weight heparin (LMWH) against coronaviridae have been reported by in vitro studies, but no in vivo evidence is yet available. We sought to know whether the timing of prophylactic doses of LMWH during the course of COVID-19 may affect the time to SAR...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3377
更新日期：2021-01-18 00:00:00
abstract：OBJECTIVE:To assess the tolerability, virological, immunological and clinical effects of nevirapine in the setting of a compassionate use programme in pretreated HIV-infected individuals. DESIGN:Retrospective observational cohort-study in 13 HIV-outpatient clinics in The Netherlands. METHODS: MAIN OUTCOME MEASURES:p...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2000-12-01 00:00:00
abstract：BACKGROUND:HIV type-1 (HIV-1) has been shown to be frequently transmitted by acutely infected patients. We investigated the relationship between the dynamics of HIV-1 transmission within recently infected patients, the HIV-1 variability and the transmission of antiretroviral drug resistance. METHODS:We included patien...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2009-01-01 00:00:00
abstract：BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor drug, could be a favourable drug for maintenance therapy in HIV-infected adolescents because it has few long-term side effects. However, data among adolescents switching from efavirenz (EFV) to RPV are limited. This study investigated the ph...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究
doi：10.3851/IMP3198
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND:The tuberculosis (TB) mortality rate of registered TB patients in Malawi is 23%, and 59% of the deaths occur in the first 2 months of treatment. HIV-related complications appear to be an important cause. Starting antiretroviral therapy early during tuberculosis treatment may improve outcome but problems ofte...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:Suboptimal doses of ribavirin have been suggested to explain the diminished efficacy of pegylated interferon (PEG-IFN) plus ribavirin in hepatitis C virus (HCV)-HIV-coinfected patients. METHODS:A cohort of 104 coinfected patients and an age-, sex- and genotype-matched cohort of HCV-monoinfected patients (n ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2008-01-01 00:00:00
abstract：:HIV escape in the central nervous system (CNS) despite undetectable viral load in the plasma has been observed and may contribute to HIV-associated neurocognitive disorders. Favouring the use of HIV drugs with a good penetration into the CNS has been advocated, leading to the establishment of the CNS penetration-effec...
journal_title：Antiviral therapy
pub_type： 评论,杂志文章
doi：10.3851/IMP2561
更新日期：2013-01-01 00:00:00
abstract：BACKGROUND:The influenza A virus accounts for serious annual viral upper respiratory tract infections. It is constantly able to modify its antigenic structure, thus evading host defence mechanisms. Moreover, currently available anti-influenza agents have a rather limited application, emphasizing the further need for ne...
journal_title：Antiviral therapy
pub_type： 杂志文章,收录出版
doi：10.3851/IMP3115
更新日期：2017-01-01 00:00:00
abstract：BACKGROUND:Scaling-up antiretroviral therapy (ART) in resource-limited settings has raised concerns of emerging HIV drug resistance (DR) and its transmission to newly infected individuals. To assess the prevalence of transmitted drug resistance (TDR) in recently HIV-infected individuals, a WHO TDR threshold survey was ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2999
更新日期：2016-01-01 00:00:00
abstract：BACKGROUND:Cidofovir (CDV) is an acyclic nucleoside phosphonate that exhibits a potent antiviral activity against several DNA viruses. In previous studies, CDV has been shown to significantly reduce the clinical severity and the viral shedding in primary caprine herpesvirus type-1 (CpHV-1) infection in goats. CpHV-1 is...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1611
更新日期：2010-01-01 00:00:00
abstract：BACKGROUND:Dyslipidaemia and lipodystrophy have been described in treated HIV patients and in a small percentage of untreated HIV patients. Lipodystrophy in these patients has been shown to be associated with a lower expression of low density lipoprotein (LDL) receptors. METHODS:We have investigated the effect of anti...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2005-01-01 00:00:00
abstract：BACKGROUND:Nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations (NAMs) can affect response to treatment with NRTIs and might also result in HIV-1 with reduced replication capacity. METHODS:A large commercial HIV-1 database (n=60,487) was analysed for the prevalence of NAMs, antiviral drug susceptibil...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2008-01-01 00:00:00
abstract：:HIV drug resistance testing is becoming an integral part of antiretroviral drug development and of patient management. The parameters that characterize the performance of both phenotypic and genotypic assays and the validation of this performance are essential to their proper use for these applications. Several princi...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：
更新日期：2000-03-01 00:00:00
abstract：BACKGROUND:Little is known about pregnancy patterns and levels of HIV RNA in HIV-infected women conceiving on highly active antiretroviral therapy (HAART) with non-suppressed viral load (VL), nor about their therapeutic management. METHODS:Linear mixed models were fitted to study changes in VL and potential associated...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究
doi：10.3851/IMP1489
更新日期：2010-01-01 00:00:00
abstract：BACKGROUND:Recently, we identified increased rates of CD4(+) T-cell apoptosis in HCV-infected HIV-positive patients as a potential mechanism for enhanced mortality in patients with HIV/HCV coinfection. Since this effect might be attributed to changes in receptor-induced apoptosis, we studied expression and function of ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1882
更新日期：2011-01-01 00:00:00
abstract：BACKGROUND:The potential use of variola virus as a biological weapon has renewed efforts in the development of antiviral agents against orthopoxviruses. ST-246 [4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-di oxo-4,6-ethenocycloprop [f]isoindol-2(1 H)-yl)-benzamide] is an anti-orthopoxvirus compound active ag...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2007-01-01 00:00:00
abstract：OBJECTIVES:Clinical disorders occurring in HIV-infected patients on antiretroviral therapy (ART) have been linked to mitochondrial dysfunction, for example, lactic acidosis and lipodystrophy. Mitochondrial membrane potential (delta psi m) is the most direct measure of the state of energization of the mitochondria. We a...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章
doi：
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:The aim of this study was to assess the long-term efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs). METHODS:A total of 272 antiretroviral-naive patients with a CD4+ T-cell count of 200-350 cells/mm3 were treated wit...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究,随机对照试验
doi：
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed...
journal_title：Antiviral therapy
pub_type： 杂志文章,随机对照试验
doi：10.3851/IMP2358
更新日期：2013-01-01 00:00:00
